1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Lithuania Pharmaceuticals and Healthcare Report Q3 2016

Lithuania Pharmaceuticals and Healthcare Report Q3 2016

  • May 2016
  • -
  • Business Monitor International
  • -
  • 78 pages

Includes 3 FREE quarterly updates

BMI View: Lithuania's pharmaceutical and healthcare market represents a modest prospect for investmentfrom multinational firms. A rising burden of chronic disease will translate into an increase in demand andsales; however, fiscal policies and the small size of the market will limit revenue earning opportunities.Headline Expenditure Projections

- Pharmaceuticals: EUR616mn (USD683mn) in 2015 to EUR633mn (USD678mn) in 2016; +2.4% inlocal currency terms and -0.7% in US dollar terms.

Forecast revised downwards from Q216.

- Healthcare: EUR2.45bn (USD2.72bn) in 2015 to EUR2.56bn (USD2.74bn) in 2016; 4.4% in localcurrency terms and 0.8% in US dollar terms. Forecast revised upwards from Q216.

Table Of Contents

Lithuania Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Lithuania 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lithuania 2012-2020) 12
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020) 20
Generic Drug Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020) 22
OTC Medicine Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Lithuania 2014-2020) 26
Table: Pharmaceutical Trade Data And Forecasts local currency (Lithuania 2014-2020) 27
Industry Risk Reward Index 28
Central And Eastern Europe Risk/Reward Index - Q3 2016 28
Lithuania Risk/Reward Index 34
Rewards 34
Risks 35
Regulatory Review 36
Intellectual Property Issues 39
Pricing Regime 39
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines 40
Reimbursement Regime 41
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines 42
Market Overview 44
Healthcare Sector 45
Table: Healthcare Resources (Lithuania 2010-2015) 46
Table: Healthcare Personnel (Lithuania 2010-2015) 46
Table: Healthcare Activity (Lithuania 2010-2015) 47
Research and Development 48
Clinical Trials 50
Epidemiology 51
Competitive Landscape 54
Research-Based Industry 54
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA) 54
Table: Multinational Market Activity 55
Generic Drugmakers 55
Pharmaceutical Distribution 56
Pharmaceutical Retail Sector 57
Company Profile 59
Valentis 59
Sanitas (Valeant) 61
Sicor Biotech (Teva) 64
Demographic Forecast 67
Table: Population Headline Indicators (Lithuania 1990-2025) 68
Table: Key Population Ratios (Lithuania 1990-2025) 68
Table: Urban/Rural Population and Life Expectancy (Lithuania 1990-2025) 69
Table: Population By Age Group (Lithuania 1990-2025) 69
Table: Population By Age Group % (Lithuania 1990-2025) 70
Glossary 72
Methodology 74
Pharmaceutical Expenditure Forecast Model 74
Healthcare Expenditure Forecast Model 74
Notes On Methodology 75
Risk/Reward Index Methodology 76
Index Overview 77
Table: Pharmaceutical Risk/Reward Index Indicators 77
Indicator Weightings 78

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.